Genitourinary Cancer

PV 04 - Poster Viewing Q&A - Session 4

TU_24_2597 - Role of Local SBRT in Metastatic Carcinoma Prostate Treated with Hormonetherapy

Tuesday, September 17
2:45 PM - 4:00 PM
Location: ASTRO Innovation Hub

Role of Local SBRT in Metastatic Carcinoma Prostate Treated with Hormonetherapy
P. S. Sridhar1, K. Roopesh2, G. H. Abilash1, M. Praveen kumar3, S. Kundavai1, A. Mandava4, N. Madhusudhan1, P. Karumanchi5, M. Hamid6, R. S. Bilimagga1, B. Ajai kumar1, and P. Anuradha7; 1Health Care Global Enterprises Ltd, Bangalore, India, 2Health Care Global enterprises ltd, Bengalore, India, 3health care global enterprises ltd, BENGALURU, India, 4health care global ltd, BENGALURU, India, 5Health Care Global enterprises Ltd, Bangalore, India, 6HCG RMC, Daresalam, Tanzania, United Republic of, 7Health care Global HOSPITAL, Bengalore, India

Purpose/Objective(s): ADT and chemotherapy is the standard of care in metastatic prostate cancer which has shown 5 year survival benefit of 40-60mths. Radiotherapy is usually used for metastatic sites as palliative treatment.Addition of local radiotherapy to prostate has shown improvement in overall survival in low tumor burden. There is limited data for local SBRT to prostate in metastatic prostate cancer on ADT.

Materials/Methods: In this stydy,35 metastatic prostate cancer patients who were treated with local SBRT,on ADT between June 2009 to Dec 2018 were retrospectively analysed for overall survival.23 out of 35 65.71% patients were oligometastases at presentation.All patients underwent baseline and follow up PSMA PET CT,MRI,PSA.After completion of 4-6 mths of ADT all patients underwent PSMA PET CT and MRI based SBRT by planning to the prostate to dose of 37.50Gy/5# alternate day,25-30Gy/5# to residual metastatic site in 17 patients. Followed by ADT until progression.

Results: In the 35 patients with Metastatic Prostate Cancer treated with robotic radiosurgery on ADT, median age 70 yrs,range 45-75 yrs.All patients tolerated the treatment well with acceptable toxicities. The mean, overall survival was estimated to be 117.53 months with a standard error of 15.834. The 5-year survival rate for this group was 87.5%.

Conclusion: In patients with metastatic prostate cancer treated with ADT addition of SBRT is well tolerated and trends towards survival benefit. In our study benefit was more for oligometastases. However this needs further validation with randomized controlled trials.

Author Disclosure: P. Sridhar: None. G.H. Abilash: None. M. Praveen kumar: None. S. Kundavai: None. N. Madhusudhan: None. P. Karumanchi: None. M. Hamid: None. R.S. Bilimagga: Honoraria; Health Care Global Enterprises Limited, INDIA. Past President; AROI. Stock; Health Care Global Enterprises INDIA.

P Anuradha

Health Care Global Limited

Presentation(s):

Send Email for P Anuradha


Assets

TU_24_2597 - Role of Local SBRT in Metastatic Carcinoma Prostate Treated with Hormonetherapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Role of Local SBRT in Metastatic Carcinoma Prostate Treated with Hormonetherapy